The drugmaker Erasca said Monday that its RAS-targeting pill shrank tumors in 40% of patients with a...
Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
The drugmaker Erasca said Monday that its RAS-targeting pill shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with...
Author: statnews.com
Read Original Article